News | March 20, 2025
Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis
FlexiTubes will showcase range of eco-friendly and innovative tube options
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Overall investment in the US facility is estimated around US$50 million
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA
Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA
Subscribe To Our Newsletter & Stay Updated
